Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
Patient Notes in 2024
Page 10 of 10 of this archive, newest first.
What has to change before a change has happened
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Sweden pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Italy pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What a 1 mL syringe does that a 0.3 mL syringe does not
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
South Africa pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Italy guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What STEP 4 and SURMOUNT-4 actually established
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
What a 1 mL syringe does that a 0.3 mL syringe does not
A unit is a volume. A dose is a mass. The bridge between them is concentration, and concentration is a number somebody has to calculate.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.